We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
Read MoreHide Full Article
Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) shares ended the last trading session 6% higher at $30.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.6% loss over the past four weeks.
Earlier this month, the company presented encouraging initial data from the multiple ascending dose portion of the phase I/II STRIVE study evaluating its functional cure candidate, IMC-M113V, for treating human immunodeficiency virus (HIV). Data from the same showed that treatment with IMC-M113V was well tolerated and demonstrated signals of dose-dependent viral control after antiretroviral treatment (ART) was interrupted. The growing optimism related to the development of IMC-M113V might have driven the recent share price rally.
This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +28.6%. Revenues are expected to be $86.81 million, up 23.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Immunocore, the consensus EPS estimate for the quarter has been revised 30.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on IMCR going forward to see if this recent jump can turn into more strength down the road.
Immunocore is part of the Zacks Medical - Biomedical and Genetics industry. Adherex Technologies Inc. (FENC - Free Report) , another stock in the same industry, closed the last trading session 0.8% lower at $6.62. FENC has returned 0.5% in the past month.
Adherex Technologies' consensus EPS estimate for the upcoming report has changed +32.4% over the past month to -$0.12. Compared to the company's year-ago EPS, this represents a change of -129.3%. Adherex Technologies currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) shares ended the last trading session 6% higher at $30.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.6% loss over the past four weeks.
Earlier this month, the company presented encouraging initial data from the multiple ascending dose portion of the phase I/II STRIVE study evaluating its functional cure candidate, IMC-M113V, for treating human immunodeficiency virus (HIV). Data from the same showed that treatment with IMC-M113V was well tolerated and demonstrated signals of dose-dependent viral control after antiretroviral treatment (ART) was interrupted. The growing optimism related to the development of IMC-M113V might have driven the recent share price rally.
This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +28.6%. Revenues are expected to be $86.81 million, up 23.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Immunocore, the consensus EPS estimate for the quarter has been revised 30.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on IMCR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Immunocore is part of the Zacks Medical - Biomedical and Genetics industry. Adherex Technologies Inc. (FENC - Free Report) , another stock in the same industry, closed the last trading session 0.8% lower at $6.62. FENC has returned 0.5% in the past month.
Adherex Technologies' consensus EPS estimate for the upcoming report has changed +32.4% over the past month to -$0.12. Compared to the company's year-ago EPS, this represents a change of -129.3%. Adherex Technologies currently boasts a Zacks Rank of #3 (Hold).